Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition

Nature Communications

Volumn 7, Issue , 2016, Pages

  Frost, Julianty ^a   Galdeano, Carles ^a   Soares, Pedro ^a   Gadd, Morgan S ^a   Grzes, Katarzyna M ^a   Ellis, Lucy ^a   Epemolu, Ola ^a   Shimamura, Satoko ^b   Bantscheff, Marcus ^b   Grandi, Paola ^b   Read, Kevin D ^a   Cantrell, Doreen A ^a   Rocha, Sonia ^a   Ciulli, Alessio ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 3ALPHA; MESSENGER RNA; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VH 298; VON HIPPEL LINDAU PROTEIN; ENZYME INHIBITOR; HIF1A PROTEIN, HUMAN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; VHL PROTEIN, HUMAN;

CHEMICAL ANALYSIS; ENZYME; ENZYME ACTIVITY; HYPOXIA; INHIBITOR;

ARTICLE; BINDING AFFINITY; CELL PERMEABILIZATION; CHEMICAL PROBE; CRYSTAL STRUCTURE; HYDROXYLATION; HYPOXIA; MOLECULAR PROBE; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL HYPOXIA; DRUG EFFECT; HUMAN; METABOLISM; MOUSE; PHYSIOLOGY; PRIMARY CELL CULTURE; TUMOR CELL LINE; UPREGULATION;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; PRIMARY CELL CULTURE; PROCOLLAGEN-PROLINE DIOXYGENASE; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84994592337     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13312     Document Type: Article

References (79)

1. Bunnage, M. E., Chekler, E. L. P., Jones, L. H. Target validation using chemical probes. Nat. Chem. Biol. 9, 195-199 (2013).
2. Arrowsmith, C. H. et al. The promise and peril of chemical probes. Nat. Chem. Biol. 11, 536-541 (2015).
3. Rabinowitz, M. H. Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses. J. Med. Chem. 56, 9369-9402 (2013).
4. Eltzschig, H. K., Bratton, D. L., Colgan, S. P. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat. Rev. Drug Discov. 13, 852-869 (2014).
5. Semenza, G. L. Oxygen sensing, homeostasis, disease. N. Engl. J. Med. 365, 537-547 (2011).
6. Kaelin, W. G., Ratcliffe, P. J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30, 393-402 (2008).
7. Majmundar, A. J., Wong, W. J., Simon, M. C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40, 294-309 (2010).
8. Kamura, T. et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284, 657-661 (1999).
9. Stebbins, C. E., Kaelin, W. G., Pavletich, N. P. Structure of the VHLElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284, 455-461 (1999).
10. Maxwell, P. H. et al. The tumour suppressor protein VHL targets h ypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999).
11. Jaakkola, P. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
12. Ivan, M. et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464-468 (2001).
13. Hon, W.-C. et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 417, 975-978 (2002).
14. Min, J.-H. et al. Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science 296, 1886-1889 (2002).
15. Wu, D., Potluri, N., Lu, J., Kim, Y., Rastinejad, F. Structural integration in hypoxia-inducible factors. Nature 524, 303-308 (2015).
16. Schofield, C. J., Ratcliffe, P. J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell. Biol. 5, 343-354 (2004).
17. Semenza, G. L. Life with oxygen. Science 318, 62-64 (2007).
18. Wang, G. L., Semenza, G. L. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82, 3610-3615 (1993).
19. Chan, D. A., Sutphin, P. D., Denko, N. C., Giaccia, A. J. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J. Biol. Chem. 277, 40112-40117 (2002).
20. McDonough, M. A. et al. Selective inhibition of factor inhibiting hypoxiainducible factor. J. Am. Chem. Soc. 127, 7680-7681 (2005).
21. Okumura, C. Y. M. et al. A new pharmacological agent (AKB-4924) stabilizes hypoxia inducible factor-1 (HIF-1) and increases skin innate defenses against bacterial infection. J. Mol. Med. 90, 1079-1089 (2012).
22. Chowdhury, R. et al. Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. ACS Chem. Biol. 8, 1488-1496 (2013).
23. Provenzano, R. et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin. J. Am. Soc. Nephrol. 11, 982-991 (2016).
24. Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736 (2009).
25. Ehrentraut, S. F. et al. Central role for endothelial human deneddylase-1/SENP8 in fine-tuning the vascular inflammatory response. J. Immunol. 190, 392-400 (2013).
26. Rentsch, A. et al. Synthesis and Pharmacology of Proteasome Inhibitors. Angew. Chem. Int. Ed. Engl. 52, 5450-5488 (2013).
27. Buckley, D. L. et al. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1a interaction. J. Am. Chem. Soc. 134, 4465-4468 (2012).
28. Van Molle, I. et al. Dissecting fragment-based lead discovery at the von hippel-lindau protein:hypoxia inducible factor 1a protein-protein interface. Chem. Biol. 19, 1300-1312 (2012).
29. Buckley, D. L. et al. Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1a. Angew. Chem. Int. Ed. Engl. 51, 11463-11467 (2012).
30. Galdeano, C. et al. Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities. J. Med. Chem. 57, 8657-8663 (2014).
31. Wells, J. A., McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009 (2007).
32. Loenarz, C. et al. Evidence for a stereoelectronic effect in human oxygen sensing. Angew. Chem. Int. Ed. Engl. 48, 1784-1787 (2009).
33. Banks, J. W. et al. The preferred conformation of a-fluoroamides. J. Chem. Soc. Perkin. Trans. 2, 2409-2411 (1999).
34. Briggs, C., O'Hagan, D., Howard, J., Yufit, D. S. The C-F bond as a tool in the conformational control of amides. J. Fluor. Chem. 119, 9-13 (2003).
35. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87 (2013).
36. Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255-265 (2011).
37. Liu, X., Testa, B., Fahr, A. Lipophilicity and its relationship with passive drug permeation. Pharm. Res. 28, 962-977 (2011).
38. Rapisarda, A. et al. Identification of small molecule inhibitors of hypoxiainducible factor 1 transcriptional activation pathway. Cancer Res. 62, 4316-4324 (2002).
39. Haase, V. H. Hypoxic regulation of erythropoiesis and iron metabolism. Am. J. Physiol. Renal Physiol. 299, F1-13 (2010).
40. Bruick, R. K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl Acad. Sci. USA 97, 9082-9087 (2000).
41. Finlay, D. K. et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8\+ T cells. J. Exp. Med. 209, 2441-2453 (2012).
42. Gnarra, J. R. et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl Acad. Sci. USA 94, 9102-9107 (1997).
43. Kapitsinou, P. P., Haase, V. H. The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ. 15, 650-659 (2008).
44. To, K. K. W., Huang, L. E. Suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) transcriptional activity by the HIF prolyl hydroxylase EGLN1. J. Biol. Chem. 280, 38102-38107 (2005).
45. Kaelin, W. G. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 8, 865-873 (2008).
46. Ramsay, G., Cantrell, D. Environmental and metabolic sensors that control T cell biology. Front. Immunol. 6, 99 (2015).
47. Mehta, R. et al. Proteasomal regulation of the hypoxic response modulates aging in C. elegans. Science 324, 1196-1198 (2009).
48. Willam, C. et al. Peptide blockade of HIFalpha degradation modulates cellular metabolism and angiogenesis. Proc. Natl Acad. Sci. USA 99, 10423-10428 (2002).
49. Li, M., Kim, W. Y. Two sides to every story: the HIF-dependent and HIFindependent functions of pVHL. J. Cell. Mol. Med. 15, 187-195 (2011).
50. Maher, E. R., Kaelin, W. G. von Hippel-Lindau disease. Medicine (Baltimore) 76, 381-391 (1997).
51. Gossage, L., Eisen, T., Maher, E. R. VHL, the story of a tumour suppressor gene. Nat. Rev. Cancer 15, 55-64 (2015).
52. Muchnik, E., Kaplan, J. HIF prolyl hydroxylase inhibitors for anemia. Expert Opin. Invest. Drugs 20, 645-656 (2011).
53. Hill, P. et al. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 19, 39-46 (2008).
54. Rey, S. et al. Synergistic effect of HIF-1alpha gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia. Proc. Natl Acad. Sci. USA 106, 20399-20404 (2009).
55. Eckle, T. et al. HIF1A reduces acute lung injury by optimizing carbohydrate metabolism in the alveolar epithelium. PLoS Biol. 11, e1001665 (2013).
56. Robinson, A. et al. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 134, 145-155 (2008).
57. Jain, I. H. et al. Hypoxia as a therapy for mitochondrial disease. Science 352, 54-61 (2016).
58. Chan, M. C., Holt-Martyn, J. P., Schofield, C. J., Ratcliffe, P. J. Pharmacological targeting of the HIF hydroxylases-a new field in medicine development. Mol. Aspects Med. 47-48, 54-75 (2016).
59. Macdougall, I. C. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin. J. Am. Soc. Nephrol. 3, 200-207 (2008).
60. Karuppagounder, S. S., Ratan, R. R. Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics J. Cereb. Blood Flow Metab. 32, 1347-1361 (2012).
61. Ortmann, B., Druker, J., Rocha, S. Cell cycle progression in response to oxygen levels. Cell Mol. Life Sci. 71, 3569-3582 (2014).
62. Toure, M., Crews, C. M. Small-molecule PROTACS: new approaches to protein degradation. Angew. Chem. Int. Ed. 55, 2-10 (2016).
63. Bulatov, E., Ciulli, A. Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation. Biochem. J. 467, 365-386 (2015).
64. Huang, X., Dixit, V. M. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 26, 484-498 (2016).
65. Zengerle, M., Chan, K.-H., Ciulli, A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem. Biol. 10, 1770-1777 (2015).
66. Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611-617 (2015).
67. Lai, A. C. et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew. Chem. Int. Ed. Engl. 55, 807-810 (2016).
68. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
69. Evans, P. R., Murshudov, G. N. How good are my data and what is the resolution Acta Crystallogr. D Biol. Crystallogr. 69, 1204-1214 (2013).
70. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D. Biol. Crystallogr. 67, 235-242 (2011).
71. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355-367 (2011).
72. Murshudov, G. N., Vagin, A. A., Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
73. Emsley, P., Lohkamp, B., Scott, W. G., Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
74. Schüttelkopf, A. W., van Aalten, D. M. F. PRODRG: a tool for highthroughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355-1363 (2004).
75. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
76. Melvin, A., Mudie, S., Rocha, S. The chromatin remodeler ISWI regulates the cellular response to hypoxia: role of FIH. Mol. Biol. Cell 22, 4171-4181 (2011).
77. Waugh, C., Sinclair, L., Finlay, D., Bayascas, J. R., Cantrell, D. Phosphoinositide (3, 4, 5)-triphosphate binding to phosphoinositide-dependent kinase 1 regulates a protein kinase B/Akt signaling threshold that dictates T-cell migration, not proliferation. Mol. Cell. Biol. 29, 5952-5962 (2009).
78. Camurri, G., Zaramella, A. High-throughput liquid chromatography/mass spectrometry method for the determination of the chromatographic hydrophobicity index. Anal. Chem. 73, 3716-3722 (2001).
79. Valko, K., Nunhuck, S., Bevan, C., Abraham, M. H., Reynolds, D. P. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J. Pharm. Sci. 92, 2236-2248 (2003).